Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:OMER News 15 October 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation (NASDAQ: OMER) is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.” The spark was the U.S. FDA approval of YARTEMLEA® (narsoplimab-wuug) as the first and only therapy indicated for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA‑TMA)—a dangerous complication that can follow stem cell transplantation. Omeros says it is finalizing preparations for a U.S. launch in January 2026, with reimbursement infrastructure already in motion. Omeros Corporation With the FDA decision now public, OMER stock pushed
25 December 2025
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see. As of 2:35 p.m. ET in after-hours trading on Wednesday, Dec. 24, 2025, OMER stock traded around $15.36, up about $6.59 (+75%) from the prior close, after swinging through a wide intraday range on heavy volume. This move matters not only because it’s dramatic — it’s because it’s tied to a hard catalyst: FDA approval of YARTEMLEA (narsoplimab‑wuug) for
24 December 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific
15 October 2025
···

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
NEW YORK, Feb 7, 2026, 07:38 EST Broadcom shares rose after Alphabet’s Google sketched out a far bigger 2026 spending plan for data centers, a shift analysts said could keep demand firm for custom AI chips and networking gear. The timing matters because Wall Street is now treating Big Tech capital spending as the tell on whether the AI boom stays hot or starts to cool. The numbers are getting too big to ignore, and investors have been punishing any hint that returns may lag the outlays. It also matters because the AI trade has split into winners and laggards.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop